Trial Profile

Phase II Study of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sintilimab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

09 May 2020 Planned End Date changed from 1 Dec 2021 to 1 Apr 2023.
09 May 2020 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
09 May 2020 Planned initiation date changed from 1 Dec 2019 to 1 Jun 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com